



NOVAGALI P H A R M A

NOVAGALI PHARMA LAUNCHES PHASE II CLINICAL TRIAL WITH CATIOPROST®

Evry (France), 14 December 2010. In accordance with the roadmap presented at its IPO, Novagali Pharma, a pharmaceutical company that develops innovative ophthalmic products, announces the initiation of a phase II clinical trial with its Catioprost® product on patients affected by glaucoma and presenting with damage to the ocular surface.

Glaucoma is an eye disease that can lead to a gradual loss of peripheral vision or even irreversible blindness. It is thought to affect over 70 million people worldwide with 60% presenting damage to the ocular surface¹. The global glaucoma market was estimated to be worth USD 5.3bn in 2009.

The most common therapeutic approach is the daily administration of medication to control intraocular pressure. However, patient age and the long-term use of formulations containing preservatives may lead to damage to the ocular surface of varying degrees of severity. Such damage undermines the observance and efficacy of treatments.

A preservative-free cationic emulsion containing 0.005% latanoprost, Catioprost® is formulated to deal with the glaucoma while treating damage to the ocular surface. Worldwide, latanoprost is the compound most often prescribed to control intraocular pressure. Catioprost® combines latanoprost with Novagali Pharma's patented Novasorb® technology, whose intrinsic properties prevent and reduce damage to the ocular surface.

The randomized phase II trial of Catioprost® should include around one hundred patients in the United States. It follows preclinical studies at Mount Sinai Hospital in New York and l'Hôpital des Quinze-Vingt in Paris. Compared to the various treatments currently on the market, these studies have already demonstrated the efficacy of Catioprost® in controlling intraocular pressure, the superiority of its safety profile* and its potential for reversing damage to the ocular surface**.

Jérôme Martinez, Chairman of Novagali Pharma's Executive Board, comments: *"Boosted by the success of our IPO and the consequent raising of €22.1m in funds, we continue to develop our clinical portfolio by focusing on the most advanced and the most promising products. Today's launch of phase II clinical trials with Catioprost® therefore fits in perfectly with the roadmap we presented. We are confident we will be able to announce further substantial progress in 2011."*

¹ Source: Prevalence of Ocular Surface Disease in Glaucoma Patients: Leung et al., Journal of Glaucoma 2008

*Liang et al. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Molecular Vision 2009; 15:1690-1699

** Liang et al. In vitro and in vivo evaluation of newly developed cationic emulsion formulations in corneal wound healing models. 2010 ARVO proceedings.



About NOVAGALI Pharma (www.novagali.com)

Founded in 2000, Novagali Pharma SA is a pharmaceutical company that develops ophthalmic innovative products for all segments of the eye. Thanks to its three proprietary technology platforms, the Company has an advanced portfolio of highly innovative products, one of which is already on sale and two of which are undergoing phase III clinical trials.

In 2009, Frost & Sullivan recognised Novagali with the Award for Industry Innovation & Advancement of the Year, for its proprietary emulsion technology platforms, and Siemens awarded the company the “Health Award” Grand Prix de l’Innovation for Novasorb®. In April 2010, Novagali Pharma and its partners in the Vitrena project obtained €9.4 million in funding from Oséo for this diabetic retinopathy project.

Novagali Pharma carried out a successful IPO in July 2010. This entailed a €22 million capital increase, making it the largest round of fundraising on the stock market in the biotechnology industry in the first half of 2010.



Contacts

Novagali
Geneviève Garrigos
VP RH & Communication
Tel: +33 (0)6 65 54 60 19

NewCap.
Investor relations
Axelle Vuillermet / Emmanuel Huynh
Tel: +33 (0) 1 44 71 94 93
E-mail: novagali@newcap.fr

Novagali Pharma is listed on NYSE Euronext Paris - Compartment C
ISIN code: FR0010915553 - Ticker: NOVA